{"id":46446,"date":"2022-07-21T18:01:57","date_gmt":"2022-07-21T16:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/"},"modified":"2022-07-21T18:01:57","modified_gmt":"2022-07-21T16:01:57","slug":"neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/","title":{"rendered":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma"},"content":{"rendered":"
\n

\n– Facial Paralysis Prevention study initiated and first patient enrolled evaluating the safety and efficacy of NTX-001 following facial nerve surgery
\n
– Ongoing Trauma Phase 2 study hits enrollment milestone with topline data expected in 2nd<\/sup> half of 2023\n<\/p>\n

<\/a><\/p>\n

PHILADELPHIA–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI), today announced the enrollment of the first patient in its Phase 2a clinical trial evaluating the safety and efficacy of NTX-001 compared to the standard of care in the treatment and prevention of facial paralysis.\n<\/p>\n

\n\u201cWe are pleased to enroll our first patient in this important Phase 2 study which will further our understanding of the potential role of NTX-001 in an area of significant unmet medical need,\u201d stated Evan Tzanis, Neuraptive\u2019 s EVP and Head of R&D.\n<\/p>\n

\nIn addition, the company provided an update on the ongoing Phase 2 Trauma study. \u201cAs we continue to emerge from the global pandemic, we have seen a significant improvement in enrollment and expect topline results in the second half of 2023,\u201d stated Tzanis. \u201cWe would like to thank the investigators and patients for their commitment to expanding treatment options that may improve patient outcomes even during the challenges of the COVID-19 pandemic.\u201d\n<\/p>\n

\n\u201cWith the initiation of our Facial Paralysis Prevention study, and our recent progress in the Trauma study, we are positioned to have two significant readouts in our proof-of-concept studies within the next 18 months, which is a significant step forward in development towards understanding an approval pathway for NTX-001,\u201d stated Robert Radie, Chairman and CEO of Neuraptive. \u201cThese studies are a testament to Neuraptive\u2019 s commitment to finding innovative solutions to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves. We look forward to providing updates on our progress in the future,\u201d said Radie.\n<\/p>\n

\nAbout the Facial Reanimation Study\n<\/p>\n

\nA Phase 2a, multicenter, prospective, randomized, subject and evaluator blinded, controlled study evaluating the safety and efficacy of NTX-001 compared to standard of care in the treatment and prevention of facial paralysis requiring surgical repair.\n<\/p>\n

\nFor more information about the Facial Reanimation Study, visit ClinicalTrials.gov at NTx20202Clinicaltrials.gov<\/a>.\n<\/p>\n

\nFor more information about the Acute Trauma Study, visit ClinicalTrials.gov at NTx20201Clinicaltrials.gov<\/a>.\n<\/p>\n

\nAbout Neuraptive\n<\/p>\n

\nNeuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations Neuraptive Therapeutics, Inc
\n
IR@neuraptive.com<\/a>\n<\/p>\n

\nOr\n<\/p>\n

\nEvan Tzanis
\n
Phone: +1-484-787-3203\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Facial Paralysis Prevention study initiated and first patient enrolled evaluating the safety and efficacy of NTX-001 following facial nerve surgery – Ongoing Trauma Phase 2 study hits enrollment milestone with topline data expected in 2nd half of 2023 PHILADELPHIA–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46446","6":"format-standard","7":"category-industry"},"yoast_head":"\nNeuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Facial Paralysis Prevention study initiated and first patient enrolled evaluating the safety and efficacy of NTX-001 following facial nerve surgery – Ongoing Trauma Phase 2 study hits enrollment milestone with topline data expected in 2nd half of 2023 PHILADELPHIA–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T16:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma\",\"datePublished\":\"2022-07-21T16:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005743\\\/en\\\/1520594\\\/21\\\/NTX_Logo2022.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/\",\"name\":\"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005743\\\/en\\\/1520594\\\/21\\\/NTX_Logo2022.jpg\",\"datePublished\":\"2022-07-21T16:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005743\\\/en\\\/1520594\\\/21\\\/NTX_Logo2022.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005743\\\/en\\\/1520594\\\/21\\\/NTX_Logo2022.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/","og_locale":"en_US","og_type":"article","og_title":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend","og_description":"– Facial Paralysis Prevention study initiated and first patient enrolled evaluating the safety and efficacy of NTX-001 following facial nerve surgery – Ongoing Trauma Phase 2 study hits enrollment milestone with topline data expected in 2nd half of 2023 PHILADELPHIA–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-21T16:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma","datePublished":"2022-07-21T16:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/"},"wordCount":479,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/","url":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/","name":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg","datePublished":"2022-07-21T16:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220721005743\/en\/1520594\/21\/NTX_Logo2022.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neuraptive-therapeutics-announces-first-patient-enrolled-in-a-phase-2-trial-of-ntx-001-for-the-prevention-of-facial-paralysis-and-provides-update-on-the-phase-2-study-of-ntx-001-in-peripheral-nerve-in\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46446"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46446\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}